Type-2 diabetes drug market set to double by 2021
The diabetes drug market is looking robust thanks to a large pipeline of new products and an ever-increasing patient population.
The market for drugs designed to treat type-2 diabetes will almost double over the next ten years, experts have predicted.
Last year, the market in the US, France, Germany, Italy, Spain, the UK and Japan was valued at around $26 billion, but research and advisory firm Decision Resources expects this figure to rise to nearly $50 billion in 2021.
This is due to the rising number of people who need treatment for the lifestyle-related condition, as well as the large pipeline of products that are expected to enter the market during the period.
One of the most exciting classes of drugs in this field is SGLT-2 inhibitors, such as dapagliflozin (AstraZeneca/Bristol-Myers Squibb) - which is expected to launch in Europe later this year - and canagliflozin (Johnson & Johnson).
Dr Donny Wong, Decision Resources' therapeutic area director, revealed: "Interviewed thought leaders consider the SGLT-2 inhibitors the most interesting agents that will emerge during the forecast period based on their weight-loss efficacy, versatility and low risk of hypoglycaemia."
Strong growth should also continue in the DPP-IV inhibitor drug class, which Decision Resources claims will enjoy a 28 per cent share of the market by 2012.
Related News
-
News Abortion pills can now be sold in retail pharmacies according to the US FDA
In the US, retail pharmacies will be allowed to sell abortion pills for the first time, after latest approval is granted by the FDA. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News Trend Report: The True Cost of API Price Rises
Download our Trend Report to discover what the current landscape of APIs and their pricing means for the pharmaceutical industry in the future. -
News Alzheimer's drug lecanemab shows reduced cognitive decline in clinical trial
A monoclonal antibody drug, named lecanemab, has been tested in a Phase III clinical trial in nearly 1800 participants, with promising results in reducing the effects of Alzheimer's disease on the brain.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance